Epipen Is Currently Experiencing a Spot Shortage, but You Have Options

a doctor's prescription pad
Tori Marsh
Tori Marsh, MPH, is on the Research Team at GoodRx, and is the resident expert on drug pricing and savings.
Posted on

One of the more popular drugs in the country, Epipen and generic epinephrine – used for the emergency treatment of severe allergic reactions –  is experiencing a spot shortage, leaving some patients without their lifesaving drug.

Over the past month, shortages have been seen in both Canada and Australia, and they both turned to the United States in an attempt to curb their shortage. Unfortunately, this shortage has now spread to the United States.

So, when do we expect to see the end of this shortage? We’re not sure, but there is good news. Unlike the national shortages that Canada and Australia are currently experiencing, spot shortages are usually driven by distribution issues, rather than manufacturing issues. According to an FDA spokesperson, “Mylan is reporting adequate supplies of EpiPen for the U.S., and we will continue to monitor this situation closely.” Fortunately, it sounds like redistributing shipments should resolve the shortage soon.

This is not the first time Epipen has been in the hot seat. In 2016, Epipen sparked public outrage in as parents learned that the child’s EpiPen had doubled to $600 for two auto-injectors, there was a 2017 recall by Mylan as their EpiPens were failing to activate, and now, this.

If you’re having trouble accessing EpiPen, or the alternative epinephrine, here are some alternatives you can talk to your doctor about:

Read here for more information about Epipen alternatives.

Drugs featured in this story

Filed under